Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Spyre Therapeutics's pe ratio was 0.8× on Jan 31, 2024.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 0.8× | +0.1 |
| 2023 | Dec 29, 2023 | 0.7× | – |
See a number that looks wrong?